{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T19:18:52Z","timestamp":1784661532485,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.repc.2018.10.011","type":"journal-article","created":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T08:48:41Z","timestamp":1556095721000},"page":"175-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Neurohormonal modulation: The new paradigm of pharmacological treatment of heart failure"],"prefix":"10.1016","volume":"38","author":[{"given":"J.","family":"Silva-Cardoso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Br\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Can\u00e1rio-Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"P\u00e1dua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Bragan\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Ferreira","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2018.10.011_bib0335","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1388-9842(02)00034-X","article-title":"Prevalence of chronic heart failure in Southwestern Europe: the EPICA study","volume":"4","author":"Ceia","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2018.10.011_bib0340","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1093\/eurheartj\/ehu299","article-title":"Cardiovascular disease in Europe 2014: epidemiological update","volume":"35","author":"Nichols","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2018.10.011_bib0345","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1186\/1471-2458-12-1126","article-title":"Changing patterns of cardiovascular diseases and cancer mortality in Portugal, 1980-2010","volume":"12","author":"Pereira","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.repc.2018.10.011_bib0350","series-title":"Portugal","article-title":"Programa nacional para as doen\u00e7as c\u00e9rebro-cardiovasculares","author":"Direc\u00e7\u00e3o Geral de Sa\u00fade","year":"2017"},{"key":"10.1016\/j.repc.2018.10.011_bib0355","doi-asserted-by":"crossref","first-page":"10","DOI":"10.20344\/amp.5909","article-title":"Heart failure: a new epidemic of cardiovascular disease","volume":"29","author":"Silva","year":"2016","journal-title":"Acta Med Port"},{"key":"10.1016\/j.repc.2018.10.011_bib0360","first-page":"1077","article-title":"Heart transplantation in Portugal: current status and future perspectives","volume":"21","author":"Silva Cardoso","year":"2002","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.repc.2018.10.011_bib0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.repc.2016.10.006","article-title":"For the improvement of Heart Failure treatment in Portugal \u2013 consensus statement","volume":"36","author":"Fonseca","year":"2017","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.repc.2018.10.011_bib0370","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ehf2.12005","article-title":"Heart failure: preventing disease and death worldwide","volume":"1","author":"Ponikowski","year":"2014","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.repc.2018.10.011_bib0375","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.repc.2017.11.010","article-title":"Heart failure in numbers: estimates for the 21st century in Portugal","volume":"37","author":"Fonseca","year":"2018","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.repc.2018.10.011_bib0380","series-title":"Portugal","article-title":"Doen\u00e7as c\u00e9rebro-cardiovasculares em n\u00fameros \u2013 2015","author":"Direc\u00e7\u00e3o Geral de Sa\u00fade","year":"2015"},{"key":"10.1016\/j.repc.2018.10.011_bib0385","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.repc.2012.10.018","article-title":"Characterization of acute heart failure hospitalizations in a Portuguese cardiology department","volume":"32","author":"Pinho-Gomes","year":"2013","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.repc.2018.10.011_bib0390","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.repc.2015.11.014","article-title":"Prevalence, predictors and prognosis of ventricular reverse remodeling in idiopathic dilated cardiomyopathy","volume":"35","author":"Amorim","year":"2016","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.repc.2018.10.011_bib0395","first-page":"4","article-title":"Recent advances in treatment of heart failure","author":"Kitai","year":"2015","journal-title":"F1000Res"},{"key":"10.1016\/j.repc.2018.10.011_bib0400","doi-asserted-by":"crossref","first-page":"14","DOI":"10.17925\/EJAE.2016.02.01.14","article-title":"LCZ696, an angiotensin\u2013neprilysin inhibitor versus enalapril in heart failure \u2013 summary of PARADIGM-HF results","volume":"2","author":"Silva Cardoso","year":"2016","journal-title":"Eur J Arrhyth Electrophysiol"},{"key":"10.1016\/j.repc.2018.10.011_bib0405","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2018.10.011_bib0410","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2018.10.011_bib0415","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.repc.2018.10.011_bib0420","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000092457","article-title":"Interactions between angiotensin ll and atrial natriuretic peptide in renomedullary interstitial cells: the role of neutral endopeptidase","volume":"103","author":"Maric","year":"2006","journal-title":"Nephron Physiol"},{"key":"10.1016\/j.repc.2018.10.011_bib0425","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2018.10.011_bib0430","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2018.10.011_bib0435","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2018.10.011_bib0440","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2018.10.011_bib0445","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/eurheartj\/ehr254","article-title":"The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis","volume":"33","year":"2012","journal-title":"Eur Heart J"},{"issue":"Suppl. 1","key":"10.1016\/j.repc.2018.10.011_bib0450","first-page":"5","article-title":"Dementia-related adverse effects in the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)","volume":"17","author":"Cannon","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2018.10.011_bib0455","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.tcm.2016.02.008","article-title":"New medications for heart failure","volume":"26","author":"Gordin","year":"2016","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.repc.2018.10.011_bib0460","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","article-title":"Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF","volume":"36","author":"Jhund","year":"2015","journal-title":"Eur Heart J"},{"issue":"Suppl. 1","key":"10.1016\/j.repc.2018.10.011_bib0465","first-page":"5","article-title":"Effect of the angiotensin receptor neprilysin inhibitor LCZ696 compared with enalapril according to age in PARADIGM-HF","volume":"17","author":"McMurray","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2018.10.011_bib0470","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/S0735-1097(16)31457-7","article-title":"Consistent benefit of sacubitril\/valsartan over enalapril, irrespective of background therapy in IN PARADIGM-HF","volume":"67","author":"Okumura","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2018.10.011_bib0475","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jacc.2015.08.878","article-title":"Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF","volume":"66","author":"Simpson","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2018.10.011_bib0480","doi-asserted-by":"crossref","first-page":"e002744","DOI":"10.1161\/CIRCHEARTFAILURE.115.002744","volume":"9","author":"Solomon","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.repc.2018.10.011_bib0485","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jchf.2014.09.001","article-title":"Combined neprilysin and renin\u2013angiotensin system inhibition for the treatment of heart failure","volume":"2","author":"Vardeny","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.repc.2018.10.011_bib0490","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/01.HYP.0000146483.78994.56","article-title":"Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition","volume":"44","author":"Cruden","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.repc.2018.10.011_bib0495","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.repc.2018.10.011_bib0500","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.repc.2018.10.011_bib0505","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2018.10.011_bib0510","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/ejhf.115","article-title":"Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)","volume":"16","author":"McMurray","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2018.10.011_bib0515","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","volume":"15","author":"McMurray","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2018.10.011_bib0520","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jacc.2016.04.047","article-title":"Influence of sacubitril\/valsartan (LCZ696) on 30-day readmission after heart failure hospitalization","volume":"68","author":"Desai","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2018.10.011_bib0525","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jchf.2016.05.002","article-title":"Efficacy of sacubitril\/valsartan relative to a prior decompensation: the PARADIGM-HF trial","volume":"4","author":"Solomon","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.repc.2018.10.011_bib0530","doi-asserted-by":"crossref","first-page":"e002560","DOI":"10.1161\/CIRCHEARTFAILURE.115.002560","article-title":"Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial","volume":"9","author":"Kristensen","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.repc.2018.10.011_bib0535","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/ejhf.580","article-title":"Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial","volume":"18","author":"Vardeny","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2018.10.011_bib0540","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"Yancy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2018.10.011_bib0545","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/eurheartj\/ehu455","article-title":"A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure","volume":"36","author":"McMurray","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2018.10.011_bib0550","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ahj.2017.02.034","article-title":"The effects of sacubitril\/valsartan on coronary outcomes in PARADIGM-HF","volume":"188","author":"Mogensen","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.repc.2018.10.011_bib0555","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","article-title":"Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.repc.2018.10.011_bib0560","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bcp.12861","article-title":"The effect of LCZ696 (sacubitril\/valsartan) on amyloid-\u03b2 concentrations in cerebrospinal fluid in healthy subjects","volume":"81","author":"Langenickel","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.repc.2018.10.011_bib0565","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1136\/heartjnl-2017-311295","article-title":"Sacubitril\/valsartan: beyond natriuretic peptides","volume":"103","author":"Singh","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.repc.2018.10.011_bib0570","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/eurjhf\/hfs204","article-title":"Baseline characteristics of patients in the reduction of events with Darbepoetin alfa in Heart Failure trial (RED-HF)","volume":"15","author":"McMurray","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2018.10.011_bib0575","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.repc.2018.10.011_bib0580","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1023\/B:CARD.0000025756.32499.6f","article-title":"The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN)","volume":"18","author":"Remme","year":"2004","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.repc.2018.10.011_bib0585","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"Yusuf","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2018.10.011_bib0590","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2018.10.011_bib0595","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ejhf.548","article-title":"Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens","volume":"18","author":"Senni","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2018.10.011_bib0600","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","article-title":"Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction","volume":"1","author":"Gaziano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.repc.2018.10.011_bib0605","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/jamacardio.2016.1724","article-title":"Potential mortality reduction with optimal implementation of angiotensin receptor neprilysin inhibitor therapy in heart failure","volume":"1","author":"Fonarow","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.repc.2018.10.011_bib0610","series-title":"Summary of product characteristics: Entresto","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.repc.2018.10.011_bib0615","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jchf.2016.12.018","article-title":"Early adoption of sacubitril\/valsartan for patients with heart failure with reduced ejection fraction: insights from get with the guidelines-heart failure (GWTG-HF)","volume":"5","author":"Luo","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.repc.2018.10.011_bib0620","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","article-title":"Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF","volume":"38","author":"Bohm","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2018.10.011_bib0625","doi-asserted-by":"crossref","first-page":"e004745","DOI":"10.1161\/CIRCHEARTFAILURE.117.004745","volume":"11","author":"Vardeny","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.repc.2018.10.011_bib0630","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ejhf.1054","article-title":"Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril\/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study","volume":"20","author":"Senni","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2018.10.011_bib0635","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/eurheartj\/ehx014","article-title":"Sacubitril\/valsartan and low blood pressure in heart failure with reduced ejection fraction","volume":"38","author":"Bruno","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2018.10.011_bib0640","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.repc.2018.10.011_bib0645","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin\u2013angiotensin system: a secondary analysis of the PARADIGM-HF trial","volume":"6","author":"Packer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.repc.2018.10.011_bib0650","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.repc.2018.10.011_bib0655","first-page":"e131","article-title":"Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure","volume":"9","author":"Langenickel","year":"2012","journal-title":"Drug Discov Today: Therapeut Strat"},{"key":"10.1016\/j.repc.2018.10.011_bib0660","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.amjcard.2007.11.012","article-title":"Biology of the natriuretic peptides","volume":"101","author":"Martinez-Rumayor","year":"2008","journal-title":"Am J Cardiol"}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255118300635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255118300635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:07:12Z","timestamp":1760108832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255118300635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0870255118300635"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2018.10.011","relation":{},"ISSN":["0870-2551"],"issn-type":[{"value":"0870-2551","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurohormonal modulation: The new paradigm of pharmacological treatment of heart failure","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2018.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}